News | May 08, 2024
AstraZeneca completes equity investment agreement with Cellectis
Cellectis is also eligible to receive an investigational new drug (IND) option fee and development
Cellectis is also eligible to receive an investigational new drug (IND) option fee and development
Sales reflect continued strong growth in oncology and vaccines
US FDA and EMA accepted filings based on the data from OCARINA II, with EU approval anticipated mid-2024 and U.S. approval anticipated September 2024
The demand in Africa for COVID-19 vaccines has declined
IgAN is a heterogeneous, progressive, rare kidney disease and is a major cause of chronic kidney disease worldwide
Enhertu now has five approved indications with the latest in HER2-expressing (IHC 3+) metastatic cancers
For the treatment of stenotic lesions of arteriovenous fistula in the haemodialysis management of chronic renal failure
Acquisition to further expand the Alexion, AstraZeneca Rare Disease pipeline beyond complement inhibition
Acquisition broadens oncology pipeline with a portfolio of novel T-cell engagers including HPN328 (MK-6070), an investigational delta-like ligand 3 (DLL3) targeting T-cell engager
Investigational cell therapy bemdaneprocel continues to be well tolerated with no major safety issues in all 12 participants in low and high dose cohorts through 18 months
Subscribe To Our Newsletter & Stay Updated
